Drugs / Apabetalone
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03655704 | Aug 2019 → Oct 2021 | pulmonary arterial hypertension | Steeve Provencher | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03160430 | Nov 2024 → Nov 2026 expected | chronic renal failure syndrome | Resverlogix Corp | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT03228940 | Nov 2022 | Fabry disease | Resverlogix Corp | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00768274 | Sep 2008 → Aug 2009 | acute coronary syndrome, atherosclerosis, hyperlipidemia | Resverlogix Corp | Completed | No outcome recorded |
| Phase 25 trials · 2 missed | ||||||
| Phase 2 | NCT01863225 | May → Jun 2013 | coronary artery disorder, hyperlipidemia | Resverlogix Corp | Terminated | No outcome recorded |
| Phase 2 | NCT01728467 | Nov 2012 → Mar 2014 | diabetes mellitus | Resverlogix Corp | Completed | No outcome recorded |
| Phase 2 | NCT01067820 | Sep 2011 → May 2013 | coronary atherosclerosis | Resverlogix Corp | Completed | Missed primary |
| Phase 2 | NCT01423188 | Aug 2011 → Jun 2012 | coronary atherosclerosis, hyperlipidemia | Resverlogix Corp | Completed | No outcome recorded |
| Phase 2 | NCT01058018 | Dec 2009 → Jun 2010 | atherosclerosis, coronary artery disorder | Resverlogix Corp | Completed | Missed primary |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06590324 | Apr → Dec 2025 overdue | post-COVID-19 disorder | Resverlogix Corp | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04894266 | Jan → Jun 2022 | COVID-19 | Resverlogix Corp | Terminated | No outcome recorded Stop: Enrollment |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT02586155 | Nov 2015 → Nov 2020 | coronary artery disorder, type 2 diabetes mellitus | Resverlogix Corp | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04915300 Comparator | Oct 2023 → Mar 2025 | pulmonary arterial hypertension | Laval University | Unknown | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Apabetalone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03655704 ↗ |
| Known as | Apabetalona | ChEMBL registry synonym — accepted as the source's own label CHEMBL2393130 ↗ |
| Known as | RVX-208 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2393130 ↗ |
| Known as | RVX000222 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01067820 ↗ |
| Action | Activate | “candidates for the treatment of dyslipidemia by increasing plasma levels of HDL through increased ApoA1 transcription” NCT01058018 ↗ |
| Modality | Small molecule | “novel class of small molecules” NCT00768274 ↗ |
| Route | Oral | “oral formulation of RVX000222” NCT00768274 ↗ |
| Target | BRD4 | “BRD4, a transcriptional regulator and target of apabetalone, has been linked to calcification.” PMID 30476723 ↗ Nov 2018 |